Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis [PDF]
, 2017 Chronic lymphocytic leukemia (CLL) is characterized by the expansion of malignant CD5(+) B lymphocytes in blood, bone marrow and lymphoid organs. CD1d-restricted invariant Natural Killer T (iNKT) cells are innate-like T lymphocytes strongly implicated in
Azzimonti, Laura +17 more
core +1 more source
Bcl-2 Inhibition Induces a Synergistic Effect in Combination with Doxorubicin in Chronic Lymphocytic Leukemia [PDF]
ImmunoAnalysis, 2022 Background: Chronic lymphocytic leukemia (CLL), a common neoplastic disease, is associated with the accumulation of B-lymphocytes in the hematopoietic organs.
Mohammad Sadeghi +6 more
doaj +1 more source
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]
, 2017 BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I +18 more
core +4 more sources
Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells [PDF]
, 2013 Purpose: Chronic lymphocytic leukemia (CLL) is currently incurable with standard chemotherapeutic agents, highlighting the need for novel therapies. Overcoming proliferative and cytoprotective signals generated within the microenvironment of lymphoid ...
Alison M. McCaig +14 more
core +1 more source
Ciencia y Tecnología Agropecuaria, 1998 A partir del análisis de muestras palinológicas de Carate 25, planicie aluvial del bajo río San Jorge ubicada en el municipio de San Marcos (Sucre, Colombia), de las investigacion es arqueológicas realizadas en dicha región y de los datos cronológicos ...
Luisa Fernanda Herrera +1 more
doaj +1 more source
Nanocarriers as Magic Bullets in the Treatment of Leukemia
Nanomaterials, 2020 Leukemia is a type of hematopoietic stem/progenitor cell malignancy characterized by the accumulation of immature cells in the blood and bone marrow. Treatment strategies mainly rely on the administration of chemotherapeutic agents, which, unfortunately,
Mohammad Houshmand +6 more
doaj +1 more source
Assessment of miR-150-5 p as diagnostic and prognostic markers of B- chronic Lymphocytic Leukemia in chronic hepatitis C [PDF]
African Journal of Gastroenterology and Hepatology, 2023 Aims: the current study aimed to investigate the role of miR-150-5 p expression as a diagnostic and prognostic marker of B- CLL among Egyptian patients with chronic hepatitis C and its impact on risk stratification and response to therapy.Patients ...
Nearmeen Rashad +6 more
doaj +1 more source
Haematologica, 2016 In 2014, ibrutinib was made available for relapsed/refractory chronic lymphocytic leukemia patients. The UK Chronic Lymphocytic Leukaemia Forum collected data from UK/Ireland patients with a minimum of 1 year follow-up with pre-planned primary endpoints;
UK CLL Forum
doaj +1 more source
Venetoclax inhibits autophagy in chronic lymphocytic leukemia cells
Autophagy Reports, 2023 Venetoclax (VCX) is a BCL2 inhibitor approved for treating B cell-derived leukemia, including chronic lymphocytic leukemia (CLL). VCX’s role in apoptosis induction is well-defined, whereas its other mechanistic roles need to be clarified. Autophagy is an
Yongqiang Chen +6 more
doaj +1 more source
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]
, 2016 Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L +9 more
core +1 more source